Medication-Assisted Treatment (MAT): A Complete Overview

What Is Medication-Assisted Treatment?

Medication-Assisted Treatment (MAT) is the use of FDA-approved medications, combined with counseling and behavioral therapies, to treat substance use disorders. The Substance Abuse and Mental Health Services Administration (SAMHSA) describes MAT as a "whole-patient" approach that addresses the medical, psychological, and social aspects of addiction. For opioid and alcohol use disorders specifically, MAT represents the gold standard of care — supported by decades of research and endorsed by every major medical organization.

Despite this overwhelming evidence, MAT remains underutilized and stigmatized. A common misconception frames MAT as "replacing one drug with another" — a characterization that fundamentally misunderstands both the pharmacology of these medications and the nature of addiction treatment. Taking prescribed buprenorphine for opioid use disorder is no more "replacing one addiction" than taking insulin for diabetes or statins for heart disease. These medications restore normal brain function, reduce dangerous cravings, and allow individuals to engage meaningfully in therapy and rebuild their lives.

Research published in the New England Journal of Medicine demonstrates that MAT reduces opioid overdose deaths by approximately 50%, decreases illicit drug use by 33-50%, improves treatment retention rates three to six fold, reduces criminal activity and HIV transmission, and improves employment and social functioning. By any objective measure, MAT is the most effective intervention available for opioid use disorders.

Buprenorphine (Suboxone, Sublocade, Zubsolv)

Buprenorphine is a partial opioid agonist — it activates opioid receptors in the brain but produces a much weaker effect than full agonists like heroin, fentanyl, or oxycodone. This unique pharmacological profile gives buprenorphine a "ceiling effect": beyond a certain dose, increasing the amount produces no additional opioid effects, making it significantly safer than full agonists and extremely difficult to overdose on when taken as prescribed.

How it works: By partially activating opioid receptors, buprenorphine eliminates withdrawal symptoms, significantly reduces cravings, and blocks the euphoric effects of other opioids. A person stabilized on buprenorphine feels normal — not high, not sedated, and not in withdrawal — and can function fully in daily life.

Formulations available:

• Suboxone (buprenorphine/naloxone): Sublingual film or tablet taken daily. The naloxone component discourages misuse — if injected, naloxone triggers immediate withdrawal symptoms
• Sublocade: Monthly subcutaneous injection that provides sustained buprenorphine release, eliminating daily dosing and compliance challenges
• Zubsolv: Sublingual tablet with enhanced bioavailability, allowing lower doses to achieve equivalent effects
• Probuphine: Subdermal implant providing six months of continuous buprenorphine delivery

Access: Since 2023, the X-waiver requirement has been eliminated, allowing any provider with a DEA license to prescribe buprenorphine for opioid use disorder. This policy change dramatically expanded access, particularly in rural and underserved areas where specialized addiction providers are scarce.

Methadone: The Proven Standard

Methadone is a full opioid agonist that has been used to treat opioid addiction since the 1960s, making it the longest-studied medication for this purpose. When taken at proper doses (typically 80-120mg daily), methadone eliminates withdrawal symptoms and cravings, blocks the effects of illicit opioids, and has a long half-life (24-36 hours) that provides stable coverage without the highs and lows of short-acting opioids.

Evidence of effectiveness: The evidence base for methadone maintenance treatment (MMT) is among the most robust in all of addiction medicine. Decades of randomized controlled trials, longitudinal studies, and real-world effectiveness data demonstrate that MMT reduces illicit opioid use by 33-69%, reduces overdose deaths by 50% or more, dramatically decreases criminal activity and injection-related HIV/hepatitis transmission, and improves employment, social functioning, and quality of life.

Access limitations: Unlike buprenorphine, methadone for addiction treatment can only be dispensed through federally certified Opioid Treatment Programs (OTPs). Patients typically must attend the clinic daily for observed dosing, at least initially, before earning take-home privileges based on compliance and stability. This requirement can create significant barriers including long commutes, scheduling conflicts with employment, and the stigma of daily clinic attendance.

Who benefits most: Methadone is particularly appropriate for individuals with severe, long-duration opioid use disorders who have not responded adequately to buprenorphine, those who require higher opioid receptor occupancy for adequate craving control, and individuals who benefit from the structure and daily accountability of OTP attendance.

Naltrexone (Vivitrol): The Opioid Blocker

Naltrexone takes a fundamentally different pharmacological approach: rather than partially activating opioid receptors, it blocks them entirely. If a person taking naltrexone uses opioids, they will experience no euphoria and minimal other effects — essentially rendering the opioid use pointless. This mechanism can extinguish drug-seeking behavior over time by breaking the association between opioid use and reward.

Vivitrol (extended-release naltrexone injection): Administered as a monthly intramuscular injection, Vivitrol eliminates daily compliance challenges and provides continuous opioid blockade for approximately 28-30 days. A multi-site clinical trial published in The Lancet demonstrated that Vivitrol significantly reduced opioid relapse compared to placebo, with participants receiving Vivitrol having 90% confirmed opioid-free weeks compared to 35% in the placebo group.

Important considerations: Naltrexone requires complete opioid abstinence for 7-14 days before initiation — administering it to someone with opioids in their system triggers precipitated withdrawal, which is extremely uncomfortable. This abstinence requirement can be a barrier for some patients, as the withdrawal period before naltrexone initiation carries relapse risk. Medically supervised detox followed by prompt Vivitrol initiation can bridge this gap.

For alcohol use disorder: Naltrexone (in both oral daily and injectable monthly formulations) is also FDA-approved for alcohol use disorder, where it reduces heavy drinking episodes and cravings. The Sinclair Method, which involves taking oral naltrexone before drinking, has accumulated evidence suggesting it can gradually reduce alcohol consumption through pharmacological extinction.

Medications for Alcohol Use Disorder

Three medications have FDA approval specifically for alcohol use disorder, and emerging research supports several additional options.

Naltrexone (discussed above) reduces alcohol cravings and the rewarding effects of drinking. The COMBINE Study — one of the largest alcohol treatment trials ever conducted — found that naltrexone combined with medical management was among the most effective treatment conditions, reducing heavy drinking days by approximately 25% compared to placebo.

Acamprosate (Campral): Stabilizes the glutamate system, which becomes hyperexcitable during alcohol withdrawal and early recovery. This neurological stabilization reduces the protracted withdrawal symptoms (anxiety, insomnia, dysphoria) that often drive relapse in the first several months of sobriety. Acamprosate is typically started 5 days after the last drink and taken three times daily.

Disulfiram (Antabuse): Creates an aversive reaction (nausea, vomiting, headache, flushing) when alcohol is consumed by blocking the enzyme aldehyde dehydrogenase. Disulfiram works best for highly motivated individuals as a "safety net" that adds a physical deterrent to the psychological commitment to abstinence. Supervised administration (by a spouse, clinic, or pharmacy) significantly improves its effectiveness.

Emerging options: Topiramate, gabapentin, and baclofen have accumulated evidence for off-label use in alcohol use disorder, though none have received FDA approval for this indication. Ongoing research into GLP-1 receptor agonists (like semaglutide) has generated preliminary but intriguing signals of reduced alcohol consumption, though rigorous clinical trials are still needed.

Overcoming Stigma and Barriers to MAT

Despite overwhelming evidence supporting its effectiveness, MAT faces persistent barriers rooted in stigma, misinformation, and systemic obstacles.

Stigma within the recovery community: Some mutual aid groups and treatment programs maintain philosophies that any medication use during recovery constitutes "not being truly sober." This attitude, while rooted in genuine concern about substance dependence, contradicts medical evidence and discourages individuals from accessing life-saving treatment. The National Alliance of Advocates for Buprenorphine Treatment and other organizations are working to change these attitudes through education and advocacy.

Barriers to access: Rural and underserved communities often lack providers authorized to prescribe buprenorphine or methadone clinics within reasonable distance. Telehealth MAT services have expanded significantly since COVID-era regulatory changes, and advocacy continues for permanent telehealth prescribing flexibility. Cost barriers can be addressed through Medicaid (which covers MAT in all 50 states), commercial insurance (required to cover MAT under parity laws), and manufacturer patient assistance programs.

If you or someone you love could benefit from medication-assisted treatment, call (855) 647-8310. Our counselors can help identify MAT-capable providers in your area, explain your options, and assist with insurance verification.